Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma Clinical Trial

Official title:
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Status Not yet recruiting

Clinical Trial Summary

The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in advanced non clear cell renal cell carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05220267
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	February 28, 2022
Completion date	December 30, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00688753` - RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe	Phase 2